Accelerating the Progress of Scleroderma Research
CONQUEST is a global, perpetual, platform clinical trial developed by the Scleroderma Research Foundation (SRF) in coordination with partner biopharmaceutical companies to accelerate the clinical development of agents for scleroderma.
This groundbreaking effort, led by the SRF, will enroll patients across more than 150 centers in 30+ countries. CONQUEST offers advantages to all stakeholders—patients, physicians, and drug innovators—and provides for a seamless transition to a global Phase 3 trial, investigation of a drug’s activity in a wide range of genetic backgrounds, as well as rapid patient enrollment. In the initial stages, the primary objective of CONQUEST is to accelerate the evaluation of the treatments for SSc-ILD (interstitial lung disease secondary to scleroderma).
By assembling a global network of high-performing centers that are dedicated to treating scleroderma, the SRF expects to make enduring contributions to the scleroderma community by creating an ecosystem designed to enable success in new drug development.
CONQUEST began recruiting patients in April 2024. We would encourage individuals who have SSc-ILD to consider participation in CONQUEST.
ENROLLMENT INFORMATION
Join the quest to advance systemic sclerosis research through CONQUEST.
Consider enrolling in the CONQUEST study, a scleroderma clinical trial for people with systemic sclerosis-associated interstitial lung disease (SSc-ILD). Participants help progress research to potentially uncover new SSc-ILD treatment options.
About CONQUEST
At this stage, the primary objective of CONQUEST is to rapidly evaluate potential treatments for interstitial lung disease associated with systemic sclerosis (SSc-ILD). Secondary objectives include global SSc outcomes, including some focused on skin and other aspects of the disease.
Learn more about CONQUEST.
This platform clinical trial is the first of its kind in rare autoimmune diseases.
The CONQUEST Steering Committee
Meet the people providing external oversight of CONQUEST.
CONQUEST in the News
Conquest has attracted broad attention from the lay and biopharma press due its impact and novelty. We are gratified by the coverage and look forward to educating our stakeholders about the opportunity.
We are on a mission.
At the Scleroderma Research Foundation, we can’t and won’t stop until we find a cure for scleroderma. Learn more about our world-class research program and educational offerings.
Contact
If you are a healthcare provider or pharmaceutical company, please email info@conquestssc.org
If you are a person with scleroderma or a caregiver, please email info@sclerodermaresearch.org
